TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06261853

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CBCT
Description: CBCT provides a three-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. CBCT radiation doses are typically in the range of 60 microSv.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 2D-OPG
Description: An OPG provides a two-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. OPG radiation doses are typically in the range of 20 microSv.
Study: NCT05865600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of guideline-directed medical therapy
Description: Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure \> 100 mmHg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of guideline-directed medical therapy
Description: Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure \> 100 mmHg.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immediate referral for invasive coronary angiography
Description: Immediate referral for invasive coronary angiography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3-months delayed referral for invasive coronary angiography
Description: 3-months delayed referral for invasive coronary angiography

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study: NCT04349605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditation involves guided breathing and mindfulness training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Description: Kundalini Yoga involves stretching, guided breathing and meditation
Study: NCT05814848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relmacabtagene Autoleucel Injection
Description: For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
Study: NCT05978427

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior trunk block
Description: will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior trunk block
Description: will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.
Study: NCT06278142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Based Intervention - GUIDED
Description: In the expert-supported application, each participant will be sent a folder to be shared by the user and the guide via Google Drive, and the user is expected to perform the application in the folder. A module is added to the folder every Monday and the participant is asked to complete the relevant module until Friday of the same week. In the following two days, a feedback message is provided by the expert, taking into account the user's responses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Based Intervention - WİTHOUT GUİDANCE
Description: The developed implementation plan is communicated to the participants without expert support and their participation is ensured. A common folder will be created with the participants accepted to the study and in the group without expert support, and the process is managed by transmitting the module to the user via the folder every Monday.
Study: NCT06198374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
Study: NCT06179238

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Patients with urinary catheter insertion during the study periods will be identified and consent will be obtained for the study. In the first stage of the study, questionnaires will be applied face to face to the experimental group and the control group. Then, education and brochures will be given to the patients in the experimental group. Patients in the experimental group will be visited and evaluated every day until the urinary catheter is removed. After the urinary catheter is removed, the patients in the experimental group and urinary catheter self-care management scale will be applied to the control group.

Intervention type: OTHER
Group type: OTHER
Intervention: without patient education
Description: without patient education
Study: NCT05237596

Intervention type: DRUG
Intervention: Glucosamine Sulfate
Description: Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
Study: NCT05364957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon device
Description: Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary
Description: The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dietary
Description: The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise intervention
Description: Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
Study: NCT06159803

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: One-to-one semi-structured interviews and Think Aloud interviews

Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: One-to-one semi-structured interviews and Think Aloud interviews
Study: NCT04757090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-trastuzumab
Description: -To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure.
Study: NCT06028607

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: QD-27
Description: Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
Study: NCT04981938

Intervention type: PROCEDURE
Intervention: Lobectomy with pulmonary artery reconstruction
Description: Lobectomy with pulmonary artery reconstruction under general anesthesia with selective intubation, by postero-lateral thoracotomy in the fifth intercostal space~Subgroups : different types of pulmonary artery reconstruction such as :~* Tangential vascular reconstruction with direct suture~* Circumferential resection and end-to-end anastomosis~* bypass reconstruction with heterologous biografts, synthetic grafts, or pericardium patch
Study: NCT05075603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Administered as standard of care as described in the package insert on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Description: Administered as standard of care as described in the package insert on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisocabtagene Maraleucel
Description: Administered as standard of care as described in the package insert on Day 0.
Study: NCT04709848

Intervention type: OTHER
Intervention: None - standard of care
Description: Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.

Intervention type: OTHER
Intervention: None - standard of care
Description: Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
Study: NCT06078163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supplementation
Description: daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rehabilitation
Description: rehabilitation protocol lasting 20 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: rehabilitation protocol lasting 20 sessions.
Study: NCT06082258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the management of functional disorders
Description: Theoritical and practical training of GP in long COVID and somatic symptom disorders management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reimbursement of 3 long consultations
Description: 3 long consultations (1 hour) reimbursed for each patient
Study: NCT05376566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochloric Acid (2 M)
Description: Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
Study: NCT05532332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg capsules
Description: an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prozac® 10 mg capsules
Description: an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
Study: NCT05666752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allium Cepa L. Peel Heated Water Extract
Description: 4 capsules/day after meal(1,200 mg/day) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules/day after meal(1,200 mg/day) for 8 weeks
Study: NCT06441578

Intervention type: DRUG
Intervention: Recombinant ADAMTS13
Description: Recombinant ADAMTS13, Intravenous injection
Study: NCT05707000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group A concentric muscle training
Description: One set of each of the following exercises will completed during each session:~* leg press,~* knee flexion,~* knee extension,~* Quad drills For each set, 12 repetitions will be performed at a resistance load of 60% of the one-repetition maximum (1RM) for that exercise. The exercises will be performed 2 times a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B fascilitatory kinesiotaping
Description: Kinesiotaping is applied on the anterior thigh (quadriceps) region starting at 1/5 of the distance between anterosuperior iliac spine (ASIS) and tibia tuberosity. The tape is applied with 20% tension of the tape. The tape was tensioned from proximal region of mid quadriceps down to tibia tuberosity and, once it reached the knee, the tape was divided in the middle allowing it to circle the joint
Study: NCT05438797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adoptive TIL-TCM transfer therapy
Description: Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
Study: NCT04179045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Description: Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
Study: NCT05108038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382, D860, D027
Description: QD, PO for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382, D860, D027
Description: QD, PO for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382, D860, D027
Description: QD, PO for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382, D860, D027
Description: QD, PO for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382, D860, D027
Description: QD, PO for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-382, D860, D027
Description: QD, PO for 7days
Study: NCT05167357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID19
Description: Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases.
Study: NCT05938556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hybrid asynchronous-synchronous group coaching program
Description: A hybrid asynchronous-synchronous program. The synchronous part has two weekly recorded live group coaching calls for four months. The asynchronous consist of 1) on-demand replies to recorded coaching calls, 2) Self-coaching through weekly self-study modules and worksheets, and 3) written Ask A Coach. Content modified per needs of APPs by a physician, a certified coach, and an APP who is also a Co-I. The curriculum has weekly themes that build. Month-1 consists of 1) Introduction to the Model, 2) How to Feel Better, 3) Defining Your Purpose, and 4) Living Your Purpose. Month-2 consists of 1) Growth Mindset, 2) Welcoming Feedback and Assessment Bias, 3) Feeling Valued and Belonging, and 4) How to Deal with Hidden Expectations. Month-3 consists of 1) Imposter Syndrome, 2) Perfectionism, 3) Approval Addiction, and 4) How to Change Your Thoughts. Month-4 consists of 1) How to deal with Ambiguity, 2) Confidence, 3) Self-Appreciation and Self-Compassion, and 4) Celebrate the New You.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual group (TAU)
Description: The treatment as usual group will consist of any structural or programmatic interventions, resources, lectures, curriculum, etc. offered at the participants' hospital of employment. Thus, this active control is designed to represent a best-case alternative to group coaching, making it a more rigorous form of control. Participants randomly assigned to TAU will also continue any structural or programmatic interventions or resources they were previously participating in.
Study: NCT04640103

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT05871736

Intervention type: OTHER
Intervention: Turkish version of Child Engagement in Daily Life Measure V2
Description: Child Engagement in Daily Life Measure V2 will be performed on both groups and GMFCS and MACS levels of children with cerebral palsy will be recorded.

Intervention type: OTHER
Intervention: Turkish version of Child Engagement in Daily Life Measure V2
Description: Child Engagement in Daily Life Measure V2 will be performed on both groups and GMFCS and MACS levels of children with cerebral palsy will be recorded.
Study: NCT04003779

Intervention type: OTHER
Group type: OTHER
Intervention: Room configuration
Description: Adjust distance, handrails, degrees of turn for participant
Study: NCT05616247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECALC
Description: Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECALC Plus Weekly Boosters
Description: Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
Study: NCT05834283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises
Description: This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat.
Study: NCT05445297

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacological cardioversion with Amiodarone
Description: Patients in this group will receive intravenous amiodarone according to the following scheme:~1. administration of 5 mg/kg body weight of amiodarone diluted in 250 ml of 5% glucose solution intravenously for 20-60 minutes, depending on the tolerability of the drug.~2. if there is no effect (recovery of SR did not occur within 60 minutes from the start of the drug administration), continue the infusion of amiodarone intravenously at a dose of 100 mg/hour until a total dose of 1200 mg is reached.

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacological cardioversion with Refralon
Description: Patients in this group will receive intravenous refralon according to the following scheme:~1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur), after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight.
Study: NCT06486116

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task Specific Physical Therapy Home Program
Description: Home exercise program based on specific findings from physical therapy evaluations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Specific Physical Therapy Home Program
Description: Home exercise program based on specific findings from physical therapy evaluations.